search
Back to results

Effect of Almonds on Immune Strength and Response to Flu Vaccination in Overweight Men (Almond Immune)

Primary Purpose

Immune Response, Inflammation

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Almond group
Control Group
Sponsored by
Loma Linda University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Immune Response focused on measuring Almonds, Immunity, Inflammation

Eligibility Criteria

40 Years - 65 Years (Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Overweight men (Basal Metabolic Index 25-32)
  • Age limit between 40-65 years
  • Be able to commute to Loma Linda University

Exclusion Criteria:

  • Intolerance or allergy to almonds
  • Bad dentures, inability to chew almonds
  • Regular intake of almonds and or other nuts
  • Use of immune boosting supplements
  • Exposure to antibiotics and corticosteroids immediately prior to study
  • Have received influenza vaccination in past 10 months
  • Uncontrolled chronic disease and psychiatric illness

Sites / Locations

  • Loma Linda University School of Public Health

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Almonds

Pretzel

Arm Description

The almond group will receive 15% of their daily energy intake in the form of almonds

The placebo group will receive an isocaloric carbohydrate based pretzel snack

Outcomes

Primary Outcome Measures

changes in lymphocyte populations
Immunophenotyping will be performed by flow cytometry to measure the number of T helper, T cytotoxic, Naïve and memory cells and B cells
changes in lymphocyte activity and cytokine production
PBMC cells will be separated from blood, activated and cultured using phytohemagglutinin (PHA). Inflammatory cytokine production will be measured in the resulting supernatant using ELISA
changes in natural killer (NK) cell activity
The NK degranulation assay will be performed on blood samples. The test will be conducted using a modified flow cytometry method that measures the expression of CD107a
changes in serum inflammatory cytokine concentration
Changes in the concentrations of the inflammatory cytokines will be performed on serum using enzyme-linked immunoassay (ELISA)
changes in complete blood count (CBC)
changes in the complete blood count will be performed on whole blood with the use of an automated hematology analyzer at a certified clinical facility
changes in neutralizing antibody titers against hemagglutinin and neuraminidase of the vaccine strain
Neutralizing antibody titers in the serum against the hemagglutinin and neuraminidase of the vaccine strain will be measured using the standard commercial ELISA kits
changes in the viral load in response to vaccination
viral load in blood will be measured using a quantitative polymerase chain reaction (qPCR) protocol as described by Ward CL, et al. (2004

Secondary Outcome Measures

changes in upper respiratory infection questionnaire score
Upper respiratory tract infections will be tracked using the Jackson and Dowling questionnaire. The questionnaire will be completed daily by participants, either manually or electronically , throughout the 28-week study period. The scale for the questionnaire is from 0-42. The higher score means worse outcome.
changes in blood vitamin E levels
Vitamin E levels in the blood will be extracted with hexane, dried and assayed for alpha and gamma tocopherol by high pressure liquid chromatography (HPLC) using a normal-phase diol column and florescence detection according to the method of Kramer and colleagues (2005).
changes in blood zinc levels
Zinc levels in blood will be analyzed in trace element- free tubes and assayed by atomic absorption spectrophotometry using standard reference material obtained from the National Institute of Standards and Technology to check the accuracy and precision of the determinations

Full Information

First Posted
July 6, 2021
Last Updated
July 5, 2023
Sponsor
Loma Linda University
search

1. Study Identification

Unique Protocol Identification Number
NCT05031663
Brief Title
Effect of Almonds on Immune Strength and Response to Flu Vaccination in Overweight Men
Acronym
Almond Immune
Official Title
Effect of Daily Consumption of Almonds on Immune Strength and Response to Flu Vaccination in Overweight Middle -Aged Men: A Randomized Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
August 12, 2021 (Actual)
Primary Completion Date
May 10, 2023 (Actual)
Study Completion Date
May 10, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Loma Linda University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This research study will test the effects of almonds on immune functions and immune response to influenza vaccine in overweight middle-aged men
Detailed Description
The proposed study is a parallel-group, free-living, observer-blind, randomized controlled dietary intervention trial on 54 overweight middle-aged men. This study will be carried out in two phases: Phase 1 will examine the effects of almonds on clinically relevant markers of immune function, and Phase 2 will assess the antibody response to influenza vaccination following almond consumption. Participants will attend a baseline clinic and will be randomized to one of two groups. The Almond group will receive 15% of daily energy intake in the form of almonds as a snack and the Control group will receive an isocaloric carbohydrate-based commercial snack (pretzels). The intervention will be for 12 weeks, at which time both group participants will receive the influenza vaccination, and continue the same dietary intervention for another 16 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Immune Response, Inflammation
Keywords
Almonds, Immunity, Inflammation

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
this will be a parallel, free-living, randomized controlled trial, where 54 middle-aged men will be randomized to receive either the almonds or a placebo snack
Masking
InvestigatorOutcomes Assessor
Masking Description
The investigator and outcome assessor will not be aware which participant is in what arm. The participant and the care provider will know about the treatment allocation
Allocation
Randomized
Enrollment
61 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Almonds
Arm Type
Experimental
Arm Description
The almond group will receive 15% of their daily energy intake in the form of almonds
Arm Title
Pretzel
Arm Type
Placebo Comparator
Arm Description
The placebo group will receive an isocaloric carbohydrate based pretzel snack
Intervention Type
Dietary Supplement
Intervention Name(s)
Almond group
Intervention Description
Participants in the Almond group will receive 15% of their daily energy intake in the form of almonds as a snack
Intervention Type
Dietary Supplement
Intervention Name(s)
Control Group
Intervention Description
Participants in the control group will receive an isocaloric carbohydrate based commercial snack (pretzel)
Primary Outcome Measure Information:
Title
changes in lymphocyte populations
Description
Immunophenotyping will be performed by flow cytometry to measure the number of T helper, T cytotoxic, Naïve and memory cells and B cells
Time Frame
baseline to 12 weeks
Title
changes in lymphocyte activity and cytokine production
Description
PBMC cells will be separated from blood, activated and cultured using phytohemagglutinin (PHA). Inflammatory cytokine production will be measured in the resulting supernatant using ELISA
Time Frame
baseline to 12 weeks
Title
changes in natural killer (NK) cell activity
Description
The NK degranulation assay will be performed on blood samples. The test will be conducted using a modified flow cytometry method that measures the expression of CD107a
Time Frame
baseline to 12 weeks
Title
changes in serum inflammatory cytokine concentration
Description
Changes in the concentrations of the inflammatory cytokines will be performed on serum using enzyme-linked immunoassay (ELISA)
Time Frame
baseline to 12 weeks
Title
changes in complete blood count (CBC)
Description
changes in the complete blood count will be performed on whole blood with the use of an automated hematology analyzer at a certified clinical facility
Time Frame
baseline to 12 weeks
Title
changes in neutralizing antibody titers against hemagglutinin and neuraminidase of the vaccine strain
Description
Neutralizing antibody titers in the serum against the hemagglutinin and neuraminidase of the vaccine strain will be measured using the standard commercial ELISA kits
Time Frame
week 12 to 20 weeks
Title
changes in the viral load in response to vaccination
Description
viral load in blood will be measured using a quantitative polymerase chain reaction (qPCR) protocol as described by Ward CL, et al. (2004
Time Frame
week 12 to 20 weeks
Secondary Outcome Measure Information:
Title
changes in upper respiratory infection questionnaire score
Description
Upper respiratory tract infections will be tracked using the Jackson and Dowling questionnaire. The questionnaire will be completed daily by participants, either manually or electronically , throughout the 28-week study period. The scale for the questionnaire is from 0-42. The higher score means worse outcome.
Time Frame
baseline to 28 weeks
Title
changes in blood vitamin E levels
Description
Vitamin E levels in the blood will be extracted with hexane, dried and assayed for alpha and gamma tocopherol by high pressure liquid chromatography (HPLC) using a normal-phase diol column and florescence detection according to the method of Kramer and colleagues (2005).
Time Frame
baseline to 28 weeks
Title
changes in blood zinc levels
Description
Zinc levels in blood will be analyzed in trace element- free tubes and assayed by atomic absorption spectrophotometry using standard reference material obtained from the National Institute of Standards and Technology to check the accuracy and precision of the determinations
Time Frame
baseline to 12 weeks

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Overweight men (Basal Metabolic Index 25-32) Age limit between 40-65 years Be able to commute to Loma Linda University Exclusion Criteria: Intolerance or allergy to almonds Bad dentures, inability to chew almonds Regular intake of almonds and or other nuts Use of immune boosting supplements Exposure to antibiotics and corticosteroids immediately prior to study Have received influenza vaccination in past 10 months Uncontrolled chronic disease and psychiatric illness
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joan Sabate, DrPh
Organizational Affiliation
Loma Linda University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Loma Linda University School of Public Health
City
Loma Linda
State/Province
California
ZIP/Postal Code
92350
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of Almonds on Immune Strength and Response to Flu Vaccination in Overweight Men

We'll reach out to this number within 24 hrs